May 29, 2020 / 2:07 PM / a month ago

BRIEF-Ligand Announces Icagen’S Expansion Of Collaboration With Roche To Develop And Commercialize Therapies For Neurological Diseases

May 29 (Reuters) - Ligand Pharmaceuticals Inc:

* LIGAND ANNOUNCES ICAGEN’S EXPANSION OF COLLABORATION WITH ROCHE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEUROLOGICAL DISEASES

* LIGAND PHARMACEUTICALS - COLLABORATION INITIATES SECOND ROCHE PROGRAM UTILIZING ICAGEN’S ION CHANNEL DRUG DISCOVERY PLATFORM

* LIGAND PHARMACEUTICALS - NEW PROGRAM IN ADDITION TO ONGOING WORK ON ANOTHER NOVEL CNS TARGET

* LIGAND PHARMACEUTICALS - UNDER TERMS OF AGREEMENT, ROCHE MADE CASH UPFRONT PAYMENT, TO PROVIDE RESEARCH FUNDING TO ICAGEN

* LIGAND PHARMACEUTICALS - ICAGEN ELIGIBLE TO POTENTIALLY RECEIVE DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS OF UP TO $274 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below